Sökning: id:"swepub:oai:lup.lub.lu.se:ba33b7f4-7705-43ed-9eb6-538a70bb0048" >
Prospective Safety ...
-
Hartman, Mark L
(författare)
Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients.
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
-
The Endocrine Society,2013
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:ba33b7f4-7705-43ed-9eb6-538a70bb0048
-
https://lup.lub.lu.se/record/3438403URI
-
https://doi.org/10.1210/jc.2012-2684DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Context:In clinical practice, the safety profile of GH replacement therapy for GH-deficient adults compared with no replacement therapy is unknown.Objective:The objective of this study was to compare adverse events (AEs) in GH-deficient adults who were GH-treated with those in GH-deficient adults who did not receive GH replacement.Design and Setting:This was a prospective observational study in the setting of US clinical practices.Patients and Outcome Measures:AEs were compared between GH-treated (n = 1988) and untreated (n = 442) GH-deficient adults after adjusting for baseline group differences and controlling the false discovery rate. The standardized mortality ratio was calculated using US mortality rates.Results:After a mean follow-up of 2.3 years, there was no significant difference in rates of death, cancer, intracranial tumor growth or recurrence, diabetes, or cardiovascular events in GH-treated compared with untreated patients. The standardized mortality ratio was not increased in either group. Unexpected AEs (GH-treated vs untreated, P ≤ .05) included insomnia (6.4% vs 2.7%), dyspnea (4.2% vs 2.0%), anxiety (3.4% vs 0.9%), sleep apnea (3.3% vs 0.9%), and decreased libido (2.1% vs 0.2%). Some of these AEs were related to baseline risk factors (including obesity and cardiopulmonary disease), higher GH dose, or concomitant GH side effects.Conclusions:In GH-deficient adults, there was no evidence for a GH treatment effect on death, cancer, intracranial tumor recurrence, diabetes, or cardiovascular events, although the follow-up period was of insufficient duration to be conclusive for these long-term events. The identification of unexpected GH-related AEs reinforces the fact that patient selection and GH dose titration are important to ensure safety of adult GH replacement.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Xu, Rong
(författare)
-
Crowe, Brenda J
(författare)
-
Robison, Leslie L
(författare)
-
Erfurth, Eva MarieLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-ee0
(författare)
-
Kleinberg, David L
(författare)
-
Zimmermann, Alan G
(författare)
-
Woodmansee, Whitney W
(författare)
-
Cutler, Gordon B
(författare)
-
Chipman, John J
(författare)
-
Melmed, Shlomo
(författare)
-
Medicin, LundSektion II
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Clinical Endocrinology and Metabolism: The Endocrine Society98:3, s. 980-9881945-71970021-972X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hartman, Mark L
-
Xu, Rong
-
Crowe, Brenda J
-
Robison, Leslie ...
-
Erfurth, Eva Mar ...
-
Kleinberg, David ...
-
visa fler...
-
Zimmermann, Alan ...
-
Woodmansee, Whit ...
-
Cutler, Gordon B
-
Chipman, John J
-
Melmed, Shlomo
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Lunds universitet